Gamida Cell
Develops solutions in the fields of cell and immune therapy.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $25.0m | Post IPO Debt | |
| Total Funding | 000k | ||
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | - | - | (3915 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | - | (3531 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | - | - | - | 1363 % |
Source: Company filings or news article
Related Content
Gamida Cell is a biopharmaceutical company focused on developing advanced cell therapies to treat cancer and rare blood diseases. Operating within the biotechnology sector, Gamida Cell primarily serves healthcare providers and patients in need of innovative treatment options. The company’s core product, Omidubicel, is an advanced cell therapy designed to enhance the success of bone marrow transplants. Gamida Cell generates revenue through the development and commercialization of its proprietary therapies, which are currently in various stages of clinical trials. The company’s business model involves extensive research and development, followed by regulatory approval and market introduction. Gamida Cell aims to address unmet medical needs by leveraging its expertise in cell therapy and immunotherapy. The company’s market includes hospitals, clinics, and specialized healthcare institutions that perform bone marrow transplants and treat hematologic malignancies. By focusing on groundbreaking clinical research and strategic partnerships, Gamida Cell strives to bring life-saving therapies to patients worldwide.
Keywords: biopharmaceutical, cell therapy, cancer treatment, rare blood diseases, Omidubicel, bone marrow transplant, clinical trials, immunotherapy, healthcare providers, biotechnology.